Abeona Therapeutics Inc. (LON:0H7R)
London flag London · Delayed Price · Currency is GBP · Price in USD
5.34
-0.13 (-2.34%)
At close: May 9, 2025

Abeona Therapeutics Company Description

Abeona Therapeutics Inc., a clinical-stage biopharmaceutical company, develops gene and cell therapies for life-threatening diseases.

Its lead clinical program is pz-cel, an autologous, cell-based gene therapy for the treatment of patients with recessive dystrophic epidermolysis bullosa.

The company also develops ABO-503 to treat X-linked retinoschisis; ABO-504 for the treatment of stargardt disease; and ABO-505 to treat autosomal dominant optic atrophy.

In addition, it is developing AAV-based gene therapy through its AIM vector platform programs. The company was formerly known as PlasmaTech Biopharmaceuticals, Inc. and changed its name to Abeona Therapeutics Inc. in June 2015.

Abeona Therapeutics Inc. was founded in 1974 and is headquartered in Cleveland, Ohio.

Abeona Therapeutics Inc.
Country United States
Founded 1974
Industry Medical - Pharmaceuticals
Sector Healthcare
Employees 136
CEO Vishwas Seshadri

Contact Details

Address:
6555 Carnegie Avenue
Cleveland, Delaware 44103
United States
Phone 646 813 4701
Website abeonatherapeutics.com

Stock Details

Ticker Symbol 0H7R
Exchange London Stock Exchange
Stock Type Common Stock
Fiscal Year January - December
Reporting Currency USD
ISIN Number US00289Y2063
SIC Code 2836

Key Executives

Name Position
Dr. Vishwas Seshadri M.B.A., Ph.D. President, Chief Executive Officer and Director
Joseph Walter Vazzano CPA Chief Financial Officer
Dr. Brendan M. O'Malley J.D., Ph.D. Chief Legal Officer
Brian Kevany Ph.D. Senior Vice President, Chief Technology Officer and CSO
Gregory Gin Vice President of Investor Relations and Corporate Communications
Alison Hardgrove Chief People Officer
Jon Voss Vice President and Head of Quality
Dr. Madhav Vasanthavada M.B.A., Ph.D. Senior Vice President, Chief Commercial Officer and Head of Business Development
Carl Denny Senior Vice President of Regulatory Affairs